吉西他滨联合顺铂治疗耐药晚期乳腺癌疗效观察

目的观察吉西他滨联合顺铂治疗蒽环类和紫杉类耐药的晚期乳腺癌的疗效与安全性。方法蒽环类和紫杉类耐药的晚期乳腺癌患者36例，采用吉西他滨（泽菲）1000mg／m2，第1、8天，静脉滴注；顺铂25mg／m2，第1～3天。静脉滴注，21天为1个周期。中位周期数为3（2～4）个周期。结果完全缓解（CR）4例（11．1％），部分缓解（PR）13例（36．1％），稳定（sD）15例（41．7％），进展（PD）4例（11．1％），总有效率（CR＋PR）为47．2％。中位疾病进展时间（TTP）为6．1个月，中位生存期为12．8个月。主要毒性为骨髓抑制和胃肠道反应。结论吉西他滨联合顺铂是治疗蒽环类和紫杉类耐药的复发或晚期乳腺癌的有效方案，毒性可耐受。

Gemcitabine Combined with Cisplatin in the Treatment of Refractory Metastatic Breast Cancer

Objective To evaluate the efficacy and toxicities of gemcitabine combined with cisplatin in the treatment of advanced breast cancer pretreated with anthraeyclin and taxane. Methods Gemcitabine （ 1 000 mg/m2） and eisplatin （25 mg/ m2 ） were given intravenously on days 1 and 8 evel7 3 weeks to 2 - 4 cycles. Results Of the 36 patients, the overall response rate was 47.2% ,including 4 cases of CR,13 cases of PR,15 eases of SD and 4 cases of PD. The median time to progression was 6.1 months and median survival time was 12. g months. The main toxicities included myelosupppression and gastrointestinal reaction. Conclusion The combination of gemcitabine and cisplatin is an effective treatment for advanced breast cancer patients with manageable toxicities.